BCR and rhabdomyosarcoma: In line with these results, our work showed a significant reduction in lactate production and the rate of the TCA cycle after exposure of the BCR::ABL1-positive cell line KCL-22 and rhabdomyosarcoma HTB-153 cells to high concentrations of imatinib accompanied by significant ATP depletion.